These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 34093430)

  • 1. Roles of Gut Microbial Metabolites in Diabetic Kidney Disease.
    Fang Q; Liu N; Zheng B; Guo F; Zeng X; Huang X; Ouyang D
    Front Endocrinol (Lausanne); 2021; 12():636175. PubMed ID: 34093430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
    Zaky A; Glastras SJ; Wong MYW; Pollock CA; Saad S
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
    Zhong C; Dai Z; Chai L; Wu L; Li J; Guo W; Zhang J; Zhang Q; Xue C; Lin H; Luo Q; Cai K
    J Clin Lab Anal; 2021 Dec; 35(12):e24062. PubMed ID: 34689373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.
    Tao P; Ji J; Wang Q; Cui M; Cao M; Xu Y
    Front Immunol; 2022; 13():1080456. PubMed ID: 36601125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.
    Mao ZH; Gao ZX; Liu DW; Liu ZS; Wu P
    Front Immunol; 2023; 14():1124704. PubMed ID: 36742307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review.
    Das S; Devi Rajeswari V; Venkatraman G; Elumalai R; Dhanasekaran S; Ramanathan G
    Transl Res; 2024 Mar; 265():71-87. PubMed ID: 37952771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.
    Das S; Gnanasambandan R
    Life Sci; 2023 Mar; 316():121414. PubMed ID: 36682521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease.
    Ma L; Zhang L; Li J; Zhang X; Xie Y; Li X; Yang B; Yang H
    Mol Med; 2023 Oct; 29(1):148. PubMed ID: 37907885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota-derived metabolites as central regulators in metabolic disorders.
    Agus A; Clément K; Sokol H
    Gut; 2021 Jun; 70(6):1174-1182. PubMed ID: 33272977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.
    Wu XQ; Zhao L; Zhao YL; He XY; Zou L; Zhao YY; Li X
    Pharm Biol; 2024 Dec; 62(1):423-435. PubMed ID: 38757785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes.
    Zhu T; Goodarzi MO
    Curr Nutr Rep; 2020 Jun; 9(2):83-93. PubMed ID: 32157661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM).
    Tanase DM; Gosav EM; Neculae E; Costea CF; Ciocoiu M; Hurjui LL; Tarniceriu CC; Maranduca MA; Lacatusu CM; Floria M; Serban IL
    Nutrients; 2020 Dec; 12(12):. PubMed ID: 33276482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
    Li DY; Tang WHW
    Semin Nephrol; 2018 Mar; 38(2):193-205. PubMed ID: 29602401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis.
    Li L; Wei T; Liu S; Wang C; Zhao M; Feng Y; Ma L; Lu Y; Fu P; Liu J
    J Cell Mol Med; 2021 Jan; 25(2):960-974. PubMed ID: 33280239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Gut Microbial Endocrine Organ in Type 2 Diabetes.
    Massey W; Brown JM
    Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33373432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between gut microbiome and cardiovascular disease.
    Peng J; Xiao X; Hu M; Zhang X
    Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice.
    Wang P; Guo R; Bai X; Cui W; Zhang Y; Li H; Shang J; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():1034818. PubMed ID: 36589853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
    Zhao ZH; Lai JK; Qiao L; Fan JG
    J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and microbiota-derived metabolites in cardiovascular diseases.
    Chen X; Zhang H; Ren S; Ding Y; Remex NS; Bhuiyan MS; Qu J; Tang X
    Chin Med J (Engl); 2023 Oct; 136(19):2269-2284. PubMed ID: 37442759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.